Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Sympatient
company
About
Sympatient is building the first digital anxiety clinic.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- €7.50M
- Industries
- Health Care,mHealth,Psychology,Therapeutics,Virtual Reality
- Founded date
- Dec 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Sympatient is creating a better future for anxiety patients. Our digital anxiety clinic offers patients the gold standard of anxiety therapy in the comfort of their own homes. By combining app-based CBT with mobile VR, we enable patients to learn about their anxiety disorders and effectively manage their fears with exposure therapy. Our therapy is accompanied by licensed therapists and fully reimbursed by all German health insurances.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€9.10M
Sympatient has raised a total of
€9.10M
in funding over 2 rounds. Their latest funding was raised on
Sep 29, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 29, 2022 | Series A | €7.50M | 1 |
Verve Ventures
|
— | Detail |
| May 28, 2020 | Seed | €1.60M | 1 |
Verve Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
1
Sympatient is funded by 1 investors.
Verve Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Verve Ventures
|
Yes | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
